Source link : https://www.newshealth.biz/health-news/fda-oks-high-concentration-of-adalimumab-biosimilar-cyltezo/
The US Food and Drug Administration (FDA) has approved the high-concentration, citrate-free formulation of adalimumab-adbm (Cyltezo), a biosimilar of Humira, Boehringer Ingelheim announced. This high-concentration formulation (100 mg/mL) offers a 50% reduction in injection volume and is available as a prefilled syringe or prefilled autoinjector. “With this FDA approval, we are now able to offer […]
Author : News Health
Publish date : 2024-05-02 16:34:30
Copyright for syndicated content belongs to the linked Source.